Skip to content

US · NRC · MEDICAL - HEALTHCARE INFORMATION SERVICES

NRC Health (NRC) intrinsic value and stock valuation

$25.16as of 2026-11-21 · Mkt cap 440.37M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NRC Health DCF and intrinsic value

InvestorsCraft values NRC with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NRC’s statements →

NRC Health Graham Number

Graham Number: $2.70d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Lincoln, NE 68508 nrchealth.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$137.4M+0.6% 5y CAGRd
20112025
Net income
$11.6M-20.8% 5y CAGRd
20112025
Free cash flow
$15.7M-15.6% 5y CAGRd
20112025
Total equity
$14M-26.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$137.4M$143.1M$148.6M$151.6M$148M
Operating income$22.6M$35.2M$40.1M$46.5M$50.3M
Net income$11.6M$24.8M$31M$31.8M$37.5M
EPSd$517.9K$1.04M$1.26M$1.27M$1.46M
Operating cash flow$26.5M$34.6M$38.1M$36.3M$46.3M
Capital expenditure-$-10.71M-$-15.45M-$-15.78M-$-9.84M-$-5.51M
Free cash flow$15.7M$19.2M$22.3M$26.4M$40.8M
Total assets$134.9M$132.5M$122.4M$130.5M$157.5M
Total debt$79M$64.4M$39M$23.4M$28.7M
Net debt$74.9M$60.2M$32.3M-$-1.64M-$-25.68M
Total equity$14M$31.3M$49M$72M$85.3M
Cash and short-term investments$4.14M$4.23M$6.65M$25M$54.4M
Income statement
20252024202320222021
Revenue$137.4M$143.1M$148.6M$151.6M$148M
Cost of revenue$60M$56.9M$56M$57.1M$52.4M
Gross profit$77.4M$86.1M$92.6M$94.5M$95.6M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$54.8M$44.9M$46.6M$42.7M$39M
Other expenses$0.00$6.02M$5.94M$5.28M$6.37M
Operating expenses$54.8M$50.9M$52.5M$48M$45.3M
Cost and expenses$114.8M$107.9M$108.5M$105M$97.7M
Interest income$110K$120K$820K$170K$10K
Interest expense$4.76M$2.6M$860K$1.21M$1.67M
Depreciation and amortization$7.62M$6.02M$5.9M$5.28M$6.37M
Ebitda$30.2M$41.3M$46M$49.3M$56.7M
Operating income$22.6M$35.2M$40.1M$46.5M$50.3M
Total other income/expenses, net-$-4.75M-$-2.5M-$-80K-$-3.73M-$-1.65M
Income before tax$17.8M$32.7M$40M$42.8M$48.6M
Income tax expense$6.24M$7.91M$8.99M$11M$11.2M
Net income$11.6M$24.8M$31M$31.8M$37.5M
Weighted average shares outstanding$22.4M$23.7M$24.5M$24.9M$25.4M
Weighted average diluted shares outstanding$22.4M$23.7M$24.7M$25.1M$25.6M
Balance sheet
20252024202320222021
Cash and short-term investments$4.14M$4.23M$6.65M$25M$54.4M
Net receivables$11.6M$11.2M$12.6M$15.3M$14.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$20.2M$19.6M$24.4M$43.7M$73.7M
Property, plant and equipment, net$40.5M$39.9M$30.3M$17.8M$13.4M
Goodwill and intangible assets$68.4M$68.8M$63.1M$63.2M$63.4M
Long-term investments$0.00$1.3M$0.00$0.00$0.00
Total non-current assets$114.7M$112.9M$98.1M$86.8M$83.8M
Total assets$134.9M$132.5M$122.4M$130.5M$157.5M
Accounts payable$4.07M$1.19M$1.3M$1.15M$1.94M
Short-term debt$4.01M$5.35M$7.82M$5.32M$5.24M
Deferred revenue$16.2M$15.8M$14.8M$15.2M$17.2M
Total current liabilities$36.6M$35.9M$36.2M$33.4M$40.4M
Long-term debt$75M$59.1M$31.1M$18.1M$23.4M
Deferred revenue, non-current$0.00$220K$0.00$0.00$0.00
Total non-current liabilities$84.3M$65.4M$37.3M$25M$31.8M
Capital lease obligations$0.00$1.73M$1.67M$370K$1.17M
Total liabilities$120.9M$101.3M$73.5M$58.4M$72.2M
Common stock$30K$30K$30K$30K$30K
Retained earnings-$-17.3M-$-17.06M-$-30.53M-$-25.18M-$-36.11M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-2.38M
Total equity$14M$31.3M$49M$72M$85.3M
Total investments$0.00$1.3M$0.00$0.00$0.00
Total debt$79M$64.4M$39M$23.4M$28.7M
Net debt$74.9M$60.2M$32.3M-$-1.64M-$-25.68M
Cash flow statement
20252024202320222021
Net income$11.6M$24.8M$31M$31.8M$37.5M
Depreciation and amortization$7.62M$6.02M$5.9M$5.28M$6.37M
Stock-based compensation$3.31M$280K$940K$1.2M$620K
Change in working capital$920K$3.84M$1.02M-$-3.35M$1.84M
Accounts receivable-$-50K$1.76M$2.08M-$-730K$340K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$170K-$-110K$180K-$-590K$0.00
Net cash provided by operating activities$26.5M$34.6M$38.1M$36.3M$46.3M
Investments in property, plant and equipment-$-10.71M-$-15.45M-$-15.78M-$-9.84M-$-5.51M
Acquisitions, net$0.00-$-4.83M$0.00$0.00-$-3M
Net cash used for investing activities-$-10.71M-$-20.28M-$-15.78M-$-9.84M-$-8.51M
Common stock issued$130K$0.00$0.00$0.00$0.00
Common stock repurchased-$-20.18M-$-30.95M-$-19.1M-$-27.62M-$-4.14M
Dividends paid-$-10.98M-$-11.45M-$-36.37M-$-20.96M-$-9.16M
Net cash used for financing activities-$-15.84M-$-16.76M-$-40.71M-$-55.58M-$-18.16M
Net change in cash-$-90K-$-2.42M-$-18.37M-$-29.34M$19.7M
Cash at end of period$4.14M$4.23M$6.65M$25M$54.4M
Operating cash flow$26.5M$34.6M$38.1M$36.3M$46.3M
Capital expenditure-$-10.71M-$-15.45M-$-15.78M-$-9.84M-$-5.51M
Free cash flow$15.7M$19.2M$22.3M$26.4M$40.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NRC Health

        National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

        CEO
        Trent Green
        Employees
        357
        Beta
        0.38

        Explore

        Frequently asked questions

        What is the intrinsic value of NRC Health (NRC)?

        NRC Health (NRC) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NRC undervalued?

        NRC trades at a price of $25.16 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.